BACKGROUND: Increasing evidence suggests that seizures and status epilepticus can be immune-mediated. We aimed to describe the clinical features of a new epileptic disorder, and to establish the target antigen and the effects of patients' antibodies on neuronal cultures. METHODS: In this observational study, we selected serum and CSF samples for antigen characterisation from 140 patients with encephalitis, seizures or status epilepticus, and antibodies to unknown neuropil antigens. The samples were obtained from worldwide referrals of patients with disorders suspected to be autoimmune between April 28, 2006, and April 25, 2013. We used samples from 75 healthy individuals and 416 patients with a range of neurological diseases as controls. We assessed the samples using immunoprecipitation, mass spectrometry, cell-based assay, and analysis of antibody effects in cultured rat hippocampal neurons with confocal microscopy. FINDINGS: Neuronal cell-membrane immunoprecipitation with serum of two index patients revealed GABAA receptor sequences. Cell-based assay with HEK293 expressing alpha1/beta3 subunits of the GABAA receptor showed high titre serum antibodies (>1:160) and CSF antibodies in six patients. All six patients (age 3-63 years, median 22 years; five male patients) developed refractory status epilepticus or epilepsia partialis continua along with extensive cortical-subcortical MRI abnormalities; four patients needed pharmacologically induced coma. Twelve of 416 control patients with other diseases, but none of the healthy controls, had low-titre GABAA receptor antibodies detectable in only serum samples, five of them also had GAD-65 antibodies. These 12 patients (age 2-74 years, median 26.5 years; seven male patients) developed a broader spectrum of symptoms probably indicative of coexisting autoimmune disorders: six had encephalitis with seizures (one with status epilepticus needing pharmacologically induced coma; one with epilepsia partialis continua), four had stiff-person syndrome (one with seizures and limbic involvement), and two had opsoclonus-myoclonus. Overall, 12 of 15 patients for whom treatment and outcome were assessable had full (three patients) or partial (nine patients) response to immunotherapy or symptomatic treatment, and three died. Patients' antibodies caused a selective reduction of GABAA receptor clusters at synapses, but not along dendrites, without altering NMDA receptors and gephyrin (a protein that anchors the GABAA receptor). INTERPRETATION: High titres of serum and CSF GABAA receptor antibodies are associated with a severe form of encephalitis with seizures, refractory status epilepticus, or both. The antibodies cause a selective reduction of synaptic GABAA receptors. The disorder often occurs with GABAergic and other coexisting autoimmune disorders and is potentially treatable.
The Epidemic of Autoantibody-Mediated Epilepsies -Insights into Pathophysiology and Yet Another Syndrome
From the remaining sample of the 416 disease control patients with other suspected autoantibody disease, the authors identified another 12 patients with GABA-A reactivity but with lower titers (<1:160). Of those 12 patients with low titers, six had encephalitis with seizures, four had stiff person, and two had opsoclonus-myoclonus. CSF samples in three patients were negative for autoantibodies to GABA-A receptors in this group, and autoantibodies were present only in serum.
All of the six patients with high titers against GABA-A receptors had some form of status epilepticus, encephalopathy, and an abnormal MRI. In the three patients in whom CSF was available, titers were positive in CSF and serum. CSF findings were mixed with inconsistently elevated protein, pleocytosis, and oligoclonal banding. Half of the patients were children. All of the patients seemed to go through a prolonged prodromic phase with altered cognition before the onset of seizures. One patient was diagnosed with a malignant thymoma postmortem, and the authors conclude that the syndrome is not associated with a malignancy. Two patients died, and four had partial or total recovery. The four who survived had a quite functional outcome with returning to work or school.
The MRI findings are quite dramatic ( Figure 4 of original paper). In one index patient, those findings seemed to improve, although in another, they seemed to persist. Unfortunately, the progression of the MRI findings in other patients was not presented. In the discussion, it is questioned whether the MRI findings were merely a result of seizure activity; however, frequently in status epilepticus, there are no MRI findings despite prolonged seizures. This finding would sup-port that the MRI findings could be related to the underlying disease and may even be typical. It is well possible that in the past, similar images may have been interpreted as acute demyelinating encephalomyelitis, especially in children.
Other autoantibody syndromes, such as anti NMDA receptor encephalitis, often show no MRI abnormalities, and antibody syndromes associated with AMPA, GABA-B, or LGI1 receptors show predominant involvement of the hippocampus (2, 3) .
The authors elegantly show that the presence of the antibodies does not decrease the overall number of GABA-A receptors but leads to loss of GABA-A receptors at the synapse with relocation at the dendrites. This could be an important mechanism for autoimmune-mediated seizures. The loss of GABA-A receptors at the synapse leads to seizures and certainly reinforces status epilepticus. It also suggests that some treatments, such as barbiturates and benzodiazepines, may be ineffective as they bind to the GABA-A receptor.
As more and more autoimmune mediated seizures and syndromes are described, they can be classified into those that are associated with autoantibodies to plasma membrane receptors or to intraneuronal antigens (Table  1) . While the intraneuronal targets seem to evoke a T cellmediated response, plasma membrane antigens (such as NMDA receptors) become internalized in plasma membrane associated syndromes and may explain reversibility (4) . Loss of synaptic receptors adds another possible mechanism. These underlying mechanisms may also explain the greater responsiveness of neural plasma membrane associated syndrome to immunosuppressive therapy. A recent study of 29 patients reports a response rate to immunosuppression and IV-IG of 87.5% in patients with syndromes associated with plasma membrane antigens, 33% with intraneuronal targets (GAD-65), and 33% with negative antibody screening (5) . Internalization of the receptors without neuronal cell death or relocation of the receptors from the synapse to the dendrite, as demonstrated by Petit-Pedrol et al., may additionally explain the reversibility of some of the syndromes (4). There was cross-reactivity with other autoantibodies in the patient cohort. In the group with high serum titers, there was reactivity with thyroid peroxidase antibodies and GAD-65 antibodies. In the group with low serum titers, there was cross-reactivity with GAD-65 and NMDA receptor antibodies. GAD-65 and thyroid peroxidase are intraneuronal antigens as compared to GABA-A or NMDA, which are plasma membrane receptors. As there was cross-reactivity, encephalitis with autoimmunity to the GABA-A receptor could be easily misidentified as a syndrome with autoimmunity against intraneuronal targets, which may have important treatment implications. On day 3 of admission, the MRI of this 16-year-old girl showed multiple cortical-subcortical abnormalities with increased FLAIR and T2 signal involving the left temporal lobe and frontal parasagittal regions (A, E). On day 10, a repeat MRI showed an increase of the size of the temporal lesion and a new cortical lesion in the left frontal lobe (B, F). Repeat MRIs on days 22 and 48 did not show substantial changes (data not shown). Another MRI done 4 months after disease onset showed many new multifocal abnormalities and diff use atrophy and increase of the size of the ventricles (C, G). A repeat MRI 2 months later (6 months after symptom onset) showed substantial improvement and resolution of the abnormalities as well as improvement of the ventricular dilatation (D, H).
In addition, the cross-reactivity of autoimmune antibodies raises the question of whether the autoantibody production presents an epiphenomena of an underlying immunologic process or whether it is the underlying pathophysiology. The demonstration of loss of synaptic GABA-A receptors could certainly explain some of the pathophysiology regarding seizures. The underlying process of inflammatory processes and central nervous system immunity certainly warrants further attention, as there is also ample evidence that epileptogenesis is related to microglial activation (6) . Their relationship to humoral processes needs to be explored in more depth.
Autoantibodies to neuronal antigens have been demonstrated in new and established epilepsy in 10% of patients (7) .
Clearly, disease-relevant antibody titers need to be identified. A sample of 74 normal controls in the Petit-Pedrol et al. study showed no reactivity to GABA-A at all, which certainly supports the pathologic value of the autoantibody. However, with the identification of more autoantibody syndromes, studying false positives in normal and other neurologic disease populations becomes more and more imperative.
Over the last decade, a multitude of autoimmune antibodies have been identified, and it seems that autoimmune encephalitis has become the new neurologic epidemic. Out of desperation, several immunosuppressive agents are often given to such patients. There is some collective clinical experience with anti-NMDA receptor encephalitis in regard to treatment (8) , but we do not know the true risk-benefit ratio. It Limbic encephalitis, chorea, cerebellar syndrome Thymoma poor needs to be studied systematically to identify which treatment is most effective and which underlying immune process is the most efficient to modulate. Typically given immunosuppression-such as with steroids, IV-IG, or cyclophosphamidemay not target the appropriate underlying mechanism and could cause more harm than good (4) . Identifying underlying pathophysiology, as attempted in this paper, will get us a step further to this goal, and establishing close collaborations with oncological researchers who have made strides in targeting specific underlying immune processes can only guide this process along.
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